Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Treprostinil in Pulmonary Hypertension Associated With Pulmonary Fibrosis
NCT02603068Phase 2Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2016
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of treprostinil in Pulmonary Hypertension Associated With Pulmonary Fibrosis, sponsored by United Therapeutics Corporation. Planned start Feb 2016; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
Pulmonary Hypertension Associated With Pulmonary Fibrosis
Beyond the preview
Go deeper on NCT02603068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603068.